Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and
Barrett J Burger1, Sarenthia M Epps1, Victor M Cardenas2
1Division of Pulmonary and Critical Care Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA.
Research Question:
Does treatment with tocilizumab increase the risk of a fungal infection in critically ill patients with coronavirus-19?
Background:
Numerous therapies have been evaluated as possible treatments for coronavirus-2019 caused by severe acute respiratory syndrome coronavirus-2. Tocilizumab is a humanized monoclonal antibody directed against the interleukin-6 receptor that has found a role as a therapy for patients with severe coronavirus-19 pneumonia. The immunomodulatory effects of tocilizumab may have the unintended consequence of predisposing recipients to secondary infections. We sought to assess the risk of invasive fungal disease and the therapeutic impact of tocilizumab on the hospital length of stay, duration of mechanical ventilation, and intensive-care-unit length of stay in critically ill patients with severe coronavirus-19 pneumonia.
Methods:
Records of critically ill patients with coronavirus-2019 admitted from March to September 2020 at our institution were reviewed. The risk for fungal infections, intensive-care-unit length of stay, hospital length of stay, and duration of mechanical ventilation in those that received tocilizumab in addition to standard coronavirus-2019 treatments was assessed.
Results:
Fifty-six critically ill patients treated with dexamethasone and remdesivir for coronavirus-2019 were included, of which 16 patients also received tocilizumab. The majority of the cohort was African American, Asian, or of other ethnic minorities (53.6%). Invasive fungal infections occurred in 10.7% of all patients, and infection rates were significantly higher in the tocilizumab group than in the control group (31.2% vs. 2.5%, risk difference [RD] = 28.8%, p < 0.01). The increased risk in the tocilizumab group was strongly associated with renal replacement therapy. There was a dose-response relationship between the risk of fungal infection and number of tocilizumab doses received, with 2.5% of infections occurring with zero doses, 20% with a single dose (RD = 17.5%), and 50% with two doses (RD = 47.5%) (trend test p < 0.001). In addition, ICU LOS (23.4 days vs. 9.0 days, p < 0.01), the duration of mechanical ventilation (18.9 vs. 3.5 days, p = 0.01), and hospital length of stay (LOS) (29.1 vs. 15.5, p < 0.01) were increased in patients that received tocilizumab.
Conclusions:
Repurposed immunomodulator therapies, such as tocilizumab, are now recommended treatments for severe coronavirus-2019 pneumonia, but safety concerns remain. In this early pandemic cohort, the addition of tocilizumab to dexamethasone was associated with an increased risk of fungal infection in those that were critically ill and received renal replacement therapy. Tocilizumab use was also associated with increased ICU and hospital LOSs and duration of mechanical ventilation.
Insights
Tocilizumab treatment in critically ill COVID-19 patients significantly increased fungal infection risk, especially in those receiving renal replacement therapy. This therapy also prolonged hospital stays and mechanical ventilation duration.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pharmacology
Background:
- Tocilizumab, an interleukin-6 receptor inhibitor, is used for severe COVID-19 pneumonia.
- Its immunomodulatory effects may increase susceptibility to secondary infections.
- The study investigated the risk of invasive fungal disease and clinical outcomes associated with tocilizumab.
Purpose of the Study:
- To determine if tocilizumab increases fungal infection risk in critically ill COVID-19 patients.
- To assess the impact of tocilizumab on hospital length of stay, mechanical ventilation duration, and ICU length of stay.
Main Methods:
- Retrospective review of critically ill COVID-19 patients from March to September 2020.
- Comparison of fungal infection rates and clinical outcomes between patients receiving tocilizumab and standard care.
- Analysis of risk factors including renal replacement therapy and tocilizumab dosage.
Main Results:
- Invasive fungal infections occurred in 31.2% of tocilizumab recipients versus 2.5% of controls (p < 0.01).
- Increased fungal risk was associated with renal replacement therapy and a dose-response relationship with tocilizumab.
- Tocilizumab use correlated with longer ICU stays (23.4 vs. 9.0 days), mechanical ventilation (18.9 vs. 3.5 days), and hospital stays (29.1 vs. 15.5 days).
Conclusions:
- Tocilizumab, while a recommended treatment for severe COVID-19, poses safety concerns.
- In critically ill patients, particularly those on renal replacement therapy, tocilizumab increased fungal infection risk.
- Tocilizumab use was linked to prolonged ICU and hospital stays and mechanical ventilation.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
08:38Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Related Concept Videos
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Acute Kidney Injury III: Clinical Manifestations
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...